convalescent plasma treatment - for COVID 19 hospitalized method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.11 [0.75, 1.62]> 110%2 studies (2 / -)69.7 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.85 [0.91, 3.77]> 10%1 study (1 / -)95.5 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1 / -)81.1 %some concernnot evaluable moderatecrucial-
clinical improvement (7-day) 0.98 [0.30, 3.20]> 10%1 study (1 / -)48.7 %some concernnot evaluable moderatecrucial-
deaths 0.74 [0.43, 1.25]< 117%4 studies (4 / -)87.2 %highnot evaluable lowcrucial-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 95,94,90,91 90, 91, 95